Skip to main content
. 2020 May 29;111(6):1933–1942. doi: 10.1111/cas.14410

TABLE 2.

Immune‐related adverse events (irAEs) by grade and need for corticosteroid therapy (CS) among patients with advanced non‐small‐cell lung cancer treated with nivolumab and chemotherapy

Arm A

N = 6

Arm B

N = 6

Arm C

N = 6

Arm D

N = 6
Regimen

Cisplatin

Gemcitabine

Nivolumab

Cisplatin

Pemetrexed

Nivolumab

Carboplatin

Paclitaxel

Bevacizumab

Nivolumab

Docetaxel

Nivolumab
irAE grade or CS Any 3‐4 CS Any 3‐4 CS Any 3‐4 CS Any 3‐4 CS
Any irAE 6 (100) 1 (16.7) 2 (33.3) 4 (66.7) 0 (0.0) 2 (33.3) 6 (100) 0 (0.0) 2 (33.3) 5 (83.3) 1 (16.7) 1 (16.7)
Skin toxicity 2 (33.3) 0 (0.0) 0 (0.0) 4 (66.7) 0 (0.0) 0 (0.0) 5 (83.3) 0 (0.0) 1 (16.7) 2 (33.3) 0 (0.0) 0 (0.0)
Rash maculopapular 2 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pruritus 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
Rash erythematous 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Rash 0 (0.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 0 (0.0) 5 (83.3) 0 (0.0) 1 (16.7) 1 (16.7) 0 (0.0) 0 (0.0)
Urticarias 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Gastrointestinal toxicity 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
Diarrhea 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
Endocrine disorders 1 (16.7) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
Hypophysitis 1 (16.7) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hypothyroidism 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
Blood thyroid‐stimulating hormone decreased 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
Hyperthyroidism 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hepatotoxicity 4 (66.7) 1 (16.7) 1 (16.7) 3 (50.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 0 (0.0) 3 (50.0) 1 (16.7) 0 (0.0)
AST increased 4 (66.7) 1 (16.7) 1 (16.7) 3 (50.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0) 3 (50.0) 1 (16.7) 0 (0.0)
ALT increased 4 (66.7) 1 (16.7) 1 (16.7) 2 (33.3) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 0 (0.0)
Blood bilirubin increased 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Bilirubin conjugated increased 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pulmonary toxicity 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 2 (33.3) 1 (16.7) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0)
Interstitial lung disease 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 2 (33.3) 1 (16.7) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0)
Renal toxicity 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Blood creatinine increased 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hypersensitivity 2 (33.3) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 3 (50.0) 0 (0.0) 1 (16.7) 2 (33.3) 0 (0.0) 1 (16.7)
Hypersensitivity 2 (33.3) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Infusion related reaction 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 1 (16.7) 2 (33.3) 0 (0.0) 1 (16.7)

Data are presented as n (%).

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.